Aprea Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Net Income	-14.29	-112.66	-37.13	-53.48	-28.06	Upgrade
Depreciation & Amortization	0.01	0.19	0.27	0.23	0.17	Upgrade
Share-Based Compensation	0.44	16.98	7.81	4.98	1.35	Upgrade
Other Operating Activities	1.66	70.48	-8.64	6.46	-0.16	Upgrade
Operating Cash Flow	-12.18	-25.01	-37.69	-41.8	-26.71	Upgrade
Capital Expenditures	-0.09	0	0	-0.03	-0.03	Upgrade
Investing Cash Flow	-0.09	0	0	-0.03	-0.03	Upgrade
Share Issuance / Repurchase	5.14	0.68	1.75	0.15	86.98	Upgrade
Other Financing Activities	-	-	-	-	5.6	Upgrade
Financing Cash Flow	5.14	0.68	1.75	0.15	92.58	Upgrade
Exchange Rate Effect	-0.01	0.04	-0	0.61	-1.42	Upgrade
Net Cash Flow	-7.13	-24.33	-35.94	-41.68	65.84	Upgrade
Free Cash Flow	-12.27	-25.01	-37.69	-41.83	-26.74	Upgrade
Free Cash Flow Margin	-2103.92%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-3.39	-15.09	-35.41	-39.59	-89.09	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).